<DOC>
	<DOCNO>NCT02690025</DOCNO>
	<brief_summary>A proof-of-concept , dose finding , control , single-center , randomize , double-blind , fix dose phase 2 trial ZP1848 patient Short Bowel Syndrome .</brief_summary>
	<brief_title>A Phase 2 Trial Testing ZP1848 Patients With SBS</brief_title>
	<detailed_description />
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>Following receipt verbal write information trial , patient must provide sign informed consent trial related activity carry . Age ≥ 18 year ≤ 90 year Stable SBS patient intestinal insufficiency failure , last surgical resection gut tissue perform least 1 year ago A stable PS volume ( &lt; 25 % change volume energy content ) four week prior randomization patient require PS Wet weight fecal excretion ≥ 1500 g/day demonstrate hospital stay prior screen least one day first baseline balance study . Stable body weight ( &lt; 5 % weight deviance three month prior screen ) Patients know suspected intestinal stricture clinical relevance judge Investigator Active inflammatory bowel disease ( IBD ) fistula screen period judge conventional mean Investigator . Crohn 's disease patient clinical remission last 12 week prior randomization Cardiac disease define : Decompensated heart failure ( NYHA class IIIIV ) and/or diagnosis unstable angina pectoris and/or myocardial infarction within last 6 month prior screen History cancer ( except resect cutaneous basal squamous cell carcinoma except situ cervical cancer ) unless document patient diseasefree state least 5 year ( except colon cancer : patient history colon cancer generally exclude ) eGFR ( MDRD formula ) &lt; 30 mL/min/1.73 m2 Clinically meaningful renal disease judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>